Jim Fink is chief investment strategist for Jim Fink's Options for Income and Velocity Trader. He has traded options for more than 20 years and generated personal profits of more than $5 million. Jim also serves as an investment analyst at Investing Daily’s flagship investing publication, Personal Finance.
Hopelessly overeducated, Jim holds a bachelor's degree from Yale University, a master's degree from Harvard's Kennedy School of Government, a law degree from Columbia University, and an MBA from the University of Virginia's Darden School of Business. For good measure, he has been a member of the Illinois and D.C. bars.
Prior to joining Investing Daily, and when not incurring student loans hiding out in academe, Jim practiced telecommunications regulatory law for nine years until he realized that he made more money trading stock options than writing briefs. After attending business school, Jim switched gears to the investment realm full-time, working for a university endowment, a private wealth management firm, an insurance and financial planning company, and as a Senior Analyst for an online investment newsletter service that encourages the wearing of funny hats.
A possible but unlikely descendant of legendary brawler and boatman Mike Fink, Jim defies his heritage, believing that investing success requires patience and analysis, not swashbuckling bravado. Besides his passion for analyzing and writing about stocks, Jim likes to hike in the desert Southwest, vacation in Las Vegas, play tennis, and feed his toddler son Cheerios.
There are lots of reasons to be upset with Facebook and its CEO Mark Zuckerberg, but its recent decision to buy back $1.92 billion in stock is not one of them. Read More
With critical meetings of the European Central Bank and the U.S. Federal Reserve scheduled to take place during the first half of September, stock-market volatility is bound to increase. Read More
U.S. energy royalty trusts have been great income investments over the past decade, but buying high yields at prices above underlying asset value can be dangerous to your wealth. Read More
Gilead Sciences (NasdaqGS: GILD) may lead the race to offer an all-oral treatment for Hepatitis C liver disease, but several other drug companies are also in the hunt. Read More
If you are concerned about a market correction or worse, investing in companies that are influenced by women is a wise move. And you might outperform in bull markets, too! Read More